Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962301 | 0.89 | USP30 (0.50) | CNR2GNEUSP30GPR119HPGDS | |
| SCHEMBL3467144 | 0.88 | CNR2 (0.46) | KDM4ECNR2USP30GPR119NAMPT | |
| SCHEMBL439486 | 0.88 | GPR119 (0.51) | KDM4EGPR119HPGDSTSHR | |
| SCHEMBL31232914 | 0.84 | GRM5 (0.48) | KDM4EUSP30RORCGPR119NAMPT | |
| SCHEMBL3001502 | 0.84 | GRM5 (0.48) | KDM4EUSP30RORCGPR119NAMPT | |
| SCHEMBL23089558 | 0.83 | KDM4E (0.47) | KDM4EUSP30RORCGPR119NAMPT | |
| SCHEMBL29814586 | 0.83 | KDM4E (0.47) | KDM4EUSP30RORCGPR119NAMPT | |
| SCHEMBL26090522 | 0.81 | KDM4E (0.46) | KDM4EUSP30RORCGPR119NAMPT | |
| SCHEMBL31654828 | 0.80 | KDM4E (0.45) | KDM4EGPR119NAMPT | |
| SCHEMBL25888711 | 0.80 | KDM4E (0.45) | KDM4EGPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | KDM4E 2255/4885CNR2 42/4885GNE 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.